1.Effect of recombinant human erythropoietin on hippocampal p-Akt and caspase-9 expressions in rats with status epilepticus and the mechanism.
Wei-ping WANG ; Zhi-qin SHI ; Jiang-hua YU ; Li GUO ; Le WANG ; Dong-liang HAN ; Dong-cai YUAN ; Ying-zhuo ZANG
Journal of Southern Medical University 2010;30(1):64-69
OBJECTIVETo observe the effect of recombinant human erythropoietin (rhuEPO) on p-Akt and caspase-9 expressions in the hippocampus of rats with status epilepticus (SE) and explore the neuroprotective mechanism of rhuEPO.
METHODSAdult male SD rats were randomized into control, PTZ, rHuEPO, LY294002 group, and DMSO groups and treated with normal saline (NS), PTZ, PTZ+rHuEPO, PTZ+LY294002+rHuEPO, and PTZ+DMSO+rHuEPO, respectively. The behavioral and electroencephalogram (EEG) changes of the rats were recorded, and the expressions of p-Akt and caspase-9 were detected using immunohistochemistry. The hippocampal expression of caspase-9 mRNA was detected using RT-PCR, and the expressions of Akt and p-Akt proteins were determined with Western blotting.
RESULTSThe p-Akt-positive cell and p-Akt protein expression increased significantly while the caspase-9-positive cell and caspase-9 mRNA expression decreased in rHuEPO group as compared with those in PTZ group (P<0.05). LY294002 treatment prior to rHuEPO injection significantly abolished the effects of rHuEPO on caspase-9 and p-Akt immunohistochemical positivity and caspase-9 mRNA and p-Akt protein expressions (P<0.05).
CONCLUSIONAdministration of rHuEPO activates the PI3K/Akt signaling pathway in SE rats and increases the expression of p-Akt protein to regulate the expression of caspase-9, a regulatory factor of the mitochondrial-dependent apoptotic pathway, and therefore provides anti-apoptotic and neuroprotective effects.
Animals ; Caspase 9 ; genetics ; metabolism ; Erythropoietin ; therapeutic use ; Hippocampus ; metabolism ; Male ; Neuroprotective Agents ; therapeutic use ; Proto-Oncogene Proteins c-akt ; genetics ; metabolism ; RNA, Messenger ; genetics ; metabolism ; Random Allocation ; Rats ; Rats, Sprague-Dawley ; Recombinant Proteins ; Status Epilepticus ; drug therapy ; metabolism
2.Lipid metabolic characteristics of functionally exhausted CD8+T cells in tumor microenvironment of hepatocellular carcinoma
Qi SHEN ; Le-Ying ZHUO ; Fang-Ming LIU ; Miao-Miao ZHANG ; Han WANG ; Wei-Ren LIU ; Duo-Jiao WU
Chinese Journal of Clinical Medicine 2017;24(4):514-518
Objective:To explore the lipid metabolic characteristics of functionally exhausted CD8+T cells in tumor microenvironment of hepatocellular carcinoma(HCC).Methods:By using flow cytometry analysis and real-time PCR to detect the functions and lipid metabolism-related proteins and genes expression of CD8+T cells in HCC and peri-tumor tissues,then the relationship between function and lipid metabolism was analyzed.Objective:The infiltrated CD8+T cells in HCC have the following characteristics: functional exhaustion(decreased interferon-γ secretion and up regulated programmed death molecule-1 expression);down regulated expression of multiple fatty acid synthases,and the decreased content of intracellular fatty acids;impaired mitochondrial structure and function(P<0.05).Conclusions:Fatty acid metabolism abnormalities are the characteristics of exhausted CD8+T cell infiltrated in HCC.
3.Clinical characteristics and prognosis of seizures in 75 children with acute lymphoblastic leukemia.
Jing LIU ; Ai Dong LU ; Ying Xi ZUO ; Jun WU ; Zhi Zhuo HUANG ; Yue Ping JIA ; Ming Ming DING ; Le Ping ZHANG ; Jiong QIN
Journal of Peking University(Health Sciences) 2022;54(5):948-953
OBJECTIVE:
To investigate the clinical characteristics, treatment, and prognosis of seizures in children with acute lymphoblastic leukemia (ALL) during chemotherapy.
METHODS:
Children with ALL with seizures during chemotherapy admitted to the Department of Pediatrics, Peking University People's Hospital from January 2010 to March 2022 were retrospectively analyzed. Clinical data including the incidence of seizure, time at seizure onset, causes, management, and prognosis were collected retrospectively.
RESULTS:
A total of 932 children with ALL were admitted during the study period, of whom, 75 (8%) were complicated with seizures during the period of chemotherapy. There were 40 males and 35 females, with a median age of 7.5 (1-17) years, and 43 cases (57.3%) occurred within the first 2 months of chemotherapy. The underlying diseases were reversible posterior encephalopathy syndrome (n=15), cerebral hemorrhage (n=10, one of whom was complicated with venous sinus thrombosis), intrathecal or systemic methotrexate administration (n=11), brain abscess (n=7, fungal infection in 3 cases, and bacterial in 4), viral encephalitis (n=2), febrile seizure (n=7), hyponatremia (n=7), hypocalcemia (n=2), and unknown cause (n=14). Sixty-four children underwent neuroimaging examination after seizure occurrence, of whom 37 (57.8%) were abnormal. The electroencephalograhpy (EEG) was performed in 44 cases and was abnormal in 24 (54.4%). Fifty-five patients remained in long-term remission with regular chemotherapy, 8 patients received hematopoietic stem cell transplantation, 9 died and 3 lost to follow-up. Symptomatic epilepsy was diagnosed in 18 cases (24%), and was well controlled in 16 with over 1 year of seizure-free. Whereas 2 cases were refractory to anti-seizure medications.
CONCLUSION
Seizures are relatively common in children with ALL, most commonly due to reversible posterior encephalopathy syndrome, methotrexate-related neurotoxicity, and cerebral hemorrhage. Seizures occurred within 2 months of chemotherapy in most cases. Neuroimaging and EEG should be performed as soon as possible after the first seizure onset to identify the etiology and to improve the treatment regimen. Some cases developed symptomatic epilepsy, with a satisfactory outcome of seizure remission mostly after concurrent antiseizure medication therapy.
Adolescent
;
Brain Diseases/complications*
;
Cerebral Hemorrhage/complications*
;
Child
;
Electroencephalography
;
Epilepsy/drug therapy*
;
Female
;
Humans
;
Male
;
Methotrexate/adverse effects*
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy*
;
Prognosis
;
Retrospective Studies